1. Patients and Families
  2. Clinical Trial Database
  3. Canadian clinical trial registry

Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

1 results found

Title
Status

 

CC-96191-AML-001 - A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Open

More information

CC-96191-AML-001 - A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Go to Health Care Provider version

DiagnosisMyeloid LeukemiaStudy StatusOpen
PhaseI
Age18 Years and older RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationCC-96191 will be administered intravenously on a 28-day Cycle
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT04789655
International Sponsor
Celgene
Principal Investigators for Canadian Sites
Princess Margaret Cancer Centre
Centres
Medical contact
N/A
Social worker/patient navigator contact
N/A
Clinical research contact
N/A

 

 

Study Description

This study will explore the safety, tolerability and efficacy of the biologic CC-96191 in acute myeloid leukemia (AML) that has come back or not responded to previous treatment. 

Inclusion Criteria
  • Patient must be 18 years or older
  • Patient must have AML that has come back (relapsed) or not responded to previous treatment
  • Patient must be willing to sign a consent form
  • Females and males must practice true abstinence or agree to approved contraceptive methods throughout the study, and during the safety follow-up period.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.